Publications by authors named "D P Gray"
Drug Development.
Alzheimers Dement
December 2024
Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.
View Article and Find Full Text PDFBackground: VG-3927 is a highly potent, selective, brain penetrant, oral small molecule TREM2 agonist that is currently under development for the treatment of Alzheimer's disease (AD). TREM2, a receptor expressed on microglia in the brain is critical to microglial function in health and in disease. Among microglia-associated AD risk genes, partial loss-of-function variants of TREM2 confer 2-3 fold increase in risk for developing AD, motivating efforts to identify pharmacological agonists targeting TREM2 as a therapeutic option.
View Article and Find Full Text PDFArticle Synopsis
- Zoonotic schistosomiasis, specifically caused by Schistosoma japonicum, is a significant health issue in countries like China, the Philippines, and Indonesia, highlighting the need for effective diagnostic tools to aid control strategies.
- The study evaluated five recombinant antigens for diagnostic use, ultimately developing a latex microsphere lateral flow immunoassay (LFIA) with promising results: a sensitivity of 80.6% and specificity of 98.0% in diagnosing schistosomiasis japonica.
- The LFIA demonstrated superior prevalence detection compared to traditional methods, revealing a higher prevalence of schistosomiasis in the tested population, indicating its potential as a rapid point-of-care diagnostic tool.
Insomnia is highly prevalent and is one of the most common sleep disorders amongst adults and children in the US. The American Academy of Sleep Medicine (AASM) convened the Quality Measures Task Force (Task Force) to perform maintenance on this quality measure set, developed to optimize management and care for patients with insomnia, as the measure set was originally developed and published in 2015. The Task Force reviewed the current medical literature, including updated clinical practice guidelines and systematic literature reviews, existing quality measures, and performance data highlighting gaps or variations in care since implementation of the original quality measure set to inform any potential revisions to the quality measures.
View Article and Find Full Text PDF